The Dublin-based company operates in two business units, BioNeurology and Elan Drug Technologies, and focuses on research, development, and commercial activities for neurodegenerative diseases like Alzheimer's and Parkinson's, as well as autoimmune diseases such as multiple sclerosis and Crohn's disease. Elan's shares are traded on the New York and Irish Stock Exchanges.